Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.62 |
| ▸ | CTSL | P07711 | 2/20 | 0.62 |
| ▸ | CTSK | P43235 | 2/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.59 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.59 |
| ▸ | TACR1 | P25103 | 2/20 | 0.59 |
| ▸ | TGM2 | P21980 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | ITGAV | P06756 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3987614 | 1.00 | FPR2 (0.62) | FPR2CTSLCTSKITGB3ITGA2B | |
| SCHEMBL479010 | 0.88 | TACR1 (0.68) | CTSLCTSKITGB3ITGA2BTACR1 | |
| SCHEMBL220648 | 0.88 | TACR1 (0.68) | CTSLCTSKITGB3ITGA2BTACR1 | |
| SCHEMBL7372270 | 0.88 | TACR1 (0.68) | CTSLCTSKITGB3ITGA2BTACR1 | |
| SCHEMBL219151 | 0.88 | TACR1 (0.68) | CTSLCTSKITGB3ITGA2BTACR1 | |
| SCHEMBL26661077 | 0.88 | TACR1 (0.68) | CTSLCTSKITGB3ITGA2BTACR1 | |
| SCHEMBL1795688 | 0.88 | TGM2 (0.60) | FPR2CTSLCTSKITGB3ITGA2B | |
| SCHEMBL19401964 | 0.88 | ITGB3 (0.65) | CTSLCTSKITGB3ITGA2BTACR1 | |
| SCHEMBL14485683 | 0.86 | ITGB3 (0.67) | ITGB3ITGA2BITGAVGPR34 | |
| SCHEMBL14485681 | 0.86 | ITGB3 (0.67) | ITGB3ITGA2BITGAVGPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1908466-B1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2014-02-19 | — | — | EP | disclosed |
| US-8344029-B2 | Substituted propanamide derivative and pharmaceutical composition containing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| CN-101267813-A | Substituted propanamide derivative and pharmaceutical composition containing the same | DAIICHI SANKYO CO LTD (JP) | 2008-09-17 | — | — | CN | disclosed |
| EP-1908466-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | PTMS, C1S, ACP3 | FPR2 3587/4885CTSL 530/4885CTSK 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.